Ohr Pharmaceutical Added to the Russell Indexes
June 30, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, June 30, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the Company was added to the Russell Global,...
Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD
June 24, 2014 07:00 ET
|
Ohr Pharmaceutical, Inc.
Patients treated with Squalamine eye drops plus Lucentis® PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN
Percentage...
Ohr Pharmaceutical to Host Conference Call and Webcast to Discuss Squalamine Interim Phase II Data in Wet-AMD
June 23, 2014 16:30 ET
|
Ohr Pharmaceutical, Inc.
Webcast to be Held on Tuesday, June 24 at 8:30am Eastern
Webcast & Slides Available at www.OhrPharmaceutical.com
NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc....
Ohr Pharmaceutical Announces Closing of SKS Ocular Acquisition; Strengthens Executive Management Team
June 02, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
Jason Slakter, MD Appointed Chief Medical Officer
Glenn L. Stoller, MD Appointed Chief Scientific Officer
Peter K. Kaiser, MD Appointed as Senior Vice President of Product Development
NEW...
DepYmed Announces Validation of Trodusquemine as a Therapeutic Candidate for HER2-positive Breast Cancer
May 27, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 27, 2014 (GLOBE NEWSWIRE) -- DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) and Cold Spring Harbor Laboratory, today announced the validation of Trodusquemine...
Ohr Pharmaceutical Announces Agreement to Acquire Technology Assets of SKS Ocular
May 15, 2014 16:01 ET
|
Ohr Pharmaceutical, Inc.
Transaction Expands Ohr's Pipeline to Include Multiple New Drug Candidates in Ophthalmology
Provides Ohr with Proprietary Sustained Release Drug Delivery Platform for Ocular Drugs
Upfront...
Ohr Pharmaceutical Announces Initiation of Investigator Sponsored Trial of Squalamine Eye Drops in Diabetic Macular Edema
May 09, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced the initiation of a Phase II...
Ohr Pharmaceutical Announces Completion of Enrollment in Phase II Clinical Trial of Squalamine Eye Drops in Wet-AMD
April 29, 2014 05:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 29, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...
Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock
April 08, 2014 09:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today...
Ohr Pharmaceutical to Present at the 26th Annual ROTH Conference
March 10, 2014 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced...